Cargando…

The Prevalence of Sarcopenic Obesity in Postmenopausal Women with a History of Breast Cancer Depending on Adopted Methodology – A Case–Control Study

INTRODUCTION: Sarcopenic obesity (SO) is characterized as the cooccurrence of sarcopenia and obesity. It is associated with many adverse health consequences, also in oncological patients. The study aimed to assess the prevalence of SO in postmenopausal women with a history of breast cancer depending...

Descripción completa

Detalles Bibliográficos
Autores principales: Kałędkiewicz, Emilia, Milewska, Magdalena, Panczyk, Mariusz, Szostak-Węgierek, Dorota
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708830/
https://www.ncbi.nlm.nih.gov/pubmed/33281453
http://dx.doi.org/10.2147/JMDH.S274660
_version_ 1783617621969600512
author Kałędkiewicz, Emilia
Milewska, Magdalena
Panczyk, Mariusz
Szostak-Węgierek, Dorota
author_facet Kałędkiewicz, Emilia
Milewska, Magdalena
Panczyk, Mariusz
Szostak-Węgierek, Dorota
author_sort Kałędkiewicz, Emilia
collection PubMed
description INTRODUCTION: Sarcopenic obesity (SO) is characterized as the cooccurrence of sarcopenia and obesity. It is associated with many adverse health consequences, also in oncological patients. The study aimed to assess the prevalence of SO in postmenopausal women with a history of breast cancer depending on adopted methodology. MATERIALS AND METHODS: The case–control study enrolled 103 women over the age of 50 with a history of breast cancer, including women who completed oncological treatment and had remained in remission for at least 5 years (group I, n=78) and women in whom the disease recurred (group II, n=25). The control group included women with no history of breast cancer (group III, n=73). RESULTS: In group II sarcopenia occurred significantly more commonly compared to both group I and the control group (for the skeletal muscle index (SMI) ≤29.20%: 13 (52%) in group II vs 16 (20.5%) in group I, p=0.004 and 3 (4.1%) in group III, p<0.001; for SMI ≤26.60%: 10 (40%) in group II vs 9 (11.5%) in group I, p=0.003 and 3 (4.1%) in group III, p<0.001; for SMI ≤33.87%: 17 (68%) in group II vs 21 (26.9%) in group I, p<0.001 and 5 (6.8%) in group III, p<0.001). Depending on the assessment criteria, SO was diagnosed in 0–11.5% of cases in group I, 0–40% of cases in group II and 0–4.1% in the control group. Intergroup differences were not statistically significant, irrespective of the adopted pair of diagnostic criteria. The highest detectability of SO was observed when SMI was combined with each of the diagnostic criteria for obesity used. DISCUSSION: SO diagnosis based on the percentage of fatty tissue mass in the body of >38% and SMI value were associated with a higher detection rate of SO in each study group, regardless of the adopted cut-off value. Similar results were obtained in each analyzed group when using the remaining diagnostic criteria for obesity and SMI value, regardless of the cut-off value.
format Online
Article
Text
id pubmed-7708830
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-77088302020-12-03 The Prevalence of Sarcopenic Obesity in Postmenopausal Women with a History of Breast Cancer Depending on Adopted Methodology – A Case–Control Study Kałędkiewicz, Emilia Milewska, Magdalena Panczyk, Mariusz Szostak-Węgierek, Dorota J Multidiscip Healthc Original Research INTRODUCTION: Sarcopenic obesity (SO) is characterized as the cooccurrence of sarcopenia and obesity. It is associated with many adverse health consequences, also in oncological patients. The study aimed to assess the prevalence of SO in postmenopausal women with a history of breast cancer depending on adopted methodology. MATERIALS AND METHODS: The case–control study enrolled 103 women over the age of 50 with a history of breast cancer, including women who completed oncological treatment and had remained in remission for at least 5 years (group I, n=78) and women in whom the disease recurred (group II, n=25). The control group included women with no history of breast cancer (group III, n=73). RESULTS: In group II sarcopenia occurred significantly more commonly compared to both group I and the control group (for the skeletal muscle index (SMI) ≤29.20%: 13 (52%) in group II vs 16 (20.5%) in group I, p=0.004 and 3 (4.1%) in group III, p<0.001; for SMI ≤26.60%: 10 (40%) in group II vs 9 (11.5%) in group I, p=0.003 and 3 (4.1%) in group III, p<0.001; for SMI ≤33.87%: 17 (68%) in group II vs 21 (26.9%) in group I, p<0.001 and 5 (6.8%) in group III, p<0.001). Depending on the assessment criteria, SO was diagnosed in 0–11.5% of cases in group I, 0–40% of cases in group II and 0–4.1% in the control group. Intergroup differences were not statistically significant, irrespective of the adopted pair of diagnostic criteria. The highest detectability of SO was observed when SMI was combined with each of the diagnostic criteria for obesity used. DISCUSSION: SO diagnosis based on the percentage of fatty tissue mass in the body of >38% and SMI value were associated with a higher detection rate of SO in each study group, regardless of the adopted cut-off value. Similar results were obtained in each analyzed group when using the remaining diagnostic criteria for obesity and SMI value, regardless of the cut-off value. Dove 2020-11-27 /pmc/articles/PMC7708830/ /pubmed/33281453 http://dx.doi.org/10.2147/JMDH.S274660 Text en © 2020 Kałędkiewicz et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Kałędkiewicz, Emilia
Milewska, Magdalena
Panczyk, Mariusz
Szostak-Węgierek, Dorota
The Prevalence of Sarcopenic Obesity in Postmenopausal Women with a History of Breast Cancer Depending on Adopted Methodology – A Case–Control Study
title The Prevalence of Sarcopenic Obesity in Postmenopausal Women with a History of Breast Cancer Depending on Adopted Methodology – A Case–Control Study
title_full The Prevalence of Sarcopenic Obesity in Postmenopausal Women with a History of Breast Cancer Depending on Adopted Methodology – A Case–Control Study
title_fullStr The Prevalence of Sarcopenic Obesity in Postmenopausal Women with a History of Breast Cancer Depending on Adopted Methodology – A Case–Control Study
title_full_unstemmed The Prevalence of Sarcopenic Obesity in Postmenopausal Women with a History of Breast Cancer Depending on Adopted Methodology – A Case–Control Study
title_short The Prevalence of Sarcopenic Obesity in Postmenopausal Women with a History of Breast Cancer Depending on Adopted Methodology – A Case–Control Study
title_sort prevalence of sarcopenic obesity in postmenopausal women with a history of breast cancer depending on adopted methodology – a case–control study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708830/
https://www.ncbi.nlm.nih.gov/pubmed/33281453
http://dx.doi.org/10.2147/JMDH.S274660
work_keys_str_mv AT kałedkiewiczemilia theprevalenceofsarcopenicobesityinpostmenopausalwomenwithahistoryofbreastcancerdependingonadoptedmethodologyacasecontrolstudy
AT milewskamagdalena theprevalenceofsarcopenicobesityinpostmenopausalwomenwithahistoryofbreastcancerdependingonadoptedmethodologyacasecontrolstudy
AT panczykmariusz theprevalenceofsarcopenicobesityinpostmenopausalwomenwithahistoryofbreastcancerdependingonadoptedmethodologyacasecontrolstudy
AT szostakwegierekdorota theprevalenceofsarcopenicobesityinpostmenopausalwomenwithahistoryofbreastcancerdependingonadoptedmethodologyacasecontrolstudy
AT kałedkiewiczemilia prevalenceofsarcopenicobesityinpostmenopausalwomenwithahistoryofbreastcancerdependingonadoptedmethodologyacasecontrolstudy
AT milewskamagdalena prevalenceofsarcopenicobesityinpostmenopausalwomenwithahistoryofbreastcancerdependingonadoptedmethodologyacasecontrolstudy
AT panczykmariusz prevalenceofsarcopenicobesityinpostmenopausalwomenwithahistoryofbreastcancerdependingonadoptedmethodologyacasecontrolstudy
AT szostakwegierekdorota prevalenceofsarcopenicobesityinpostmenopausalwomenwithahistoryofbreastcancerdependingonadoptedmethodologyacasecontrolstudy